U.S. markets close in 2 hours 45 minutes

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
7,895.00+31.00 (+0.39%)
At close: 4:35PM BST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close7,864.00
Bid7,905.00 x 0
Ask7,905.00 x 0
Day's Range7,842.82 - 7,918.44
52 Week Range71.46 - 10,120.00
Avg. Volume2,925,090
Market Cap103.642B
Beta (5Y Monthly)0.21
PE Ratio (TTM)36.72
EPS (TTM)215.00
Earnings DateJul 29, 2021
Forward Dividend & Yield2.07 (2.63%)
Ex-Dividend DateFeb 25, 2021
1y Target Est78.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      UPDATE 2-WHO chief urges COVID-19 vaccine makers to advance doses for COVAX

      The head of the World Health Organization called on COVID-19 vaccine manufacturers to make shots available to the COVAX vaccine-sharing facility earlier than planned due to a supply shortfall left by Indian export disruptions. COVAX, which supplies doses to poorer countries, relies heavily on India's Serum Institute's exports of the AstraZeneca shot but many of these are instead being used by the country as it battles a massive second wave of infections. The head of UNICEF on Monday asked wealthy G7 countries ahead of a summit next month to donate supplies as an emergency measure to make up the shortfall estimated at 140 million doses by end-May.

    • AstraZeneca's Farxiga Flunks Late-Stage COVID-19 Study

      AstraZeneca's Farxiga Flunks Late-Stage COVID-19 Study

      AstraZeneca plc (NASDAQ: AZN) presented detailed data from the DARE-19 Phase 3 trial at the American College of Cardiology, evaluating Farxiga (dapagliflozin) to treat hospitalized COVID-19 patients who are at risk of developing serious complications. The trial did not achieve statistical significance for the primary endpoint of prevention measuring organ dysfunction and all-cause mortality, and the primary endpoint of recovery measuring a change in clinical status at 30 days. The Phase 3 trial had enrolled 1,250 hospitalized pandemic patients with underlying conditions. For 30 days, patients were treated daily with either a placebo or dapagliflozin, and they continued that routine regardless of disease progression. Researchers found that 11.2% of dapagliflozin patients died or suffered organ failure - one of the study’s primary endpoints, compared with 13.8% of placebo patients. During the study follow-up, 6.6% of patients in the dapagliflozin group died versus 8.6% in the placebo group. The secondary endpoint of recovery, mostly measured as time to hospital discharge, was similar between the two groups. Despite the failure, it was observed that patients on Farxiga posted numerically fewer serious side effects than placebo in DARE-19 with two non-severe cases of diabetic ketoacidosis observed, both in the Farxiga arm and in patients with prior history of Type 2 diabetes. In the Farxiga arm, there were 21 reports of kidney injury compared with 34 in the placebo group. Meanwhile, there were two reports of ketoacidosis among the Farxiga group compared with none in the placebo arm. See the ACC presentation here. Price Action: AZN shares are trading 0.40% higher at $55.43 during the premarket session on the last check Monday. See more from BenzingaClick here for options trades from BenzingaUK Study Answers Question If Two Doses Of COVID-19 Vaccines Can Be Mix-Matched?UK Rethinks COVID-19 Antibody Supply Deal With AstraZeneca: Bloomberg© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • AstraZeneca Isn't Counting On Its Covid Vaccine — Is AZN Stock A Buy?
      Investor's Business Daily

      AstraZeneca Isn't Counting On Its Covid Vaccine — Is AZN Stock A Buy?

      AstraZeneca stock has yo-yoed as challenges mount for its coronavirus vaccine. But the company's 2021 guidance, raised in April, doesn't count on the Covid vaccine. Is AZN stock a buy?